PREVALENCE OF CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME AMONG OLDER WOMEN WITH BREAST CANCER IN THE 2011-2021 SEER-MEDICARE DATA
Author(s)
Li-Wei Wu, MS, Yeijin Kim, MS, Chanhyun Park, PhD;
The University of Texas at Austin, Health Outcomes Division, College of Pharmacy, Austin, TX, USA
The University of Texas at Austin, Health Outcomes Division, College of Pharmacy, Austin, TX, USA
OBJECTIVES: Cardiovascular-Kidney-Metabolic (CKM) syndrome significantly contributes to morbidity and mortality. It is particularly relevant in older women with breast cancer due to inherent cardiometabolic vulnerability and treatment-related cardiotoxicity. However, the burden of CKM syndrome in this group remains poorly characterized. We aimed to assess the prevalence and stage distribution of CKM syndrome among older women with breast cancer.
METHODS: This U.S. population-based cohort study used the 2010-2021 SEER-Medicare database. We identified women aged ≥66 years with incident breast cancer diagnosed from 2011 to 2021. CKM syndrome (stages 1-4b) was identified using ICD-9/ICD-10 codes during the 12 months before breast cancer diagnosis; women were classified by their most severe stage using a claims-based CKM staging algorithm. Annual CKM prevalence was summarized, with CKM stage distributions across calendar years compared using chi-square tests. Subgroup analyses examined CKM prevalence by age, race, and cancer stage.
RESULTS: Among 271,421 older women with breast cancer, 90.2% had pre-existing CKM syndrome. Women with advanced CKM (stages 3-4) were older at cancer diagnosis, more likely to be non-Hispanic Black women, and less likely to receive surgery, radiation, or chemotherapy. From 2011 to 2021, the prevalence of stage 2 CKM increased (41.9% to 46.4%), while stage 4a declined (43.0% to 36.6%); other stages remained stable. Stage 2 CKM was more common among younger women (66-74 years), White women, and early-stage tumors, whereas stage 4a was more prevalent in older women, non-Hispanic Black women, and those with distant-stage cancer.
CONCLUSIONS: Pre-existing CKM syndrome remains highly prevalent among older women with breast cancer, with stage-specific patterns varying across calendar years, cancer stage, and demographic characteristics. These findings highlight substantial heterogeneity in cardiometabolic health and support considering CKM burden in clinical risk assessment across subgroups.
METHODS: This U.S. population-based cohort study used the 2010-2021 SEER-Medicare database. We identified women aged ≥66 years with incident breast cancer diagnosed from 2011 to 2021. CKM syndrome (stages 1-4b) was identified using ICD-9/ICD-10 codes during the 12 months before breast cancer diagnosis; women were classified by their most severe stage using a claims-based CKM staging algorithm. Annual CKM prevalence was summarized, with CKM stage distributions across calendar years compared using chi-square tests. Subgroup analyses examined CKM prevalence by age, race, and cancer stage.
RESULTS: Among 271,421 older women with breast cancer, 90.2% had pre-existing CKM syndrome. Women with advanced CKM (stages 3-4) were older at cancer diagnosis, more likely to be non-Hispanic Black women, and less likely to receive surgery, radiation, or chemotherapy. From 2011 to 2021, the prevalence of stage 2 CKM increased (41.9% to 46.4%), while stage 4a declined (43.0% to 36.6%); other stages remained stable. Stage 2 CKM was more common among younger women (66-74 years), White women, and early-stage tumors, whereas stage 4a was more prevalent in older women, non-Hispanic Black women, and those with distant-stage cancer.
CONCLUSIONS: Pre-existing CKM syndrome remains highly prevalent among older women with breast cancer, with stage-specific patterns varying across calendar years, cancer stage, and demographic characteristics. These findings highlight substantial heterogeneity in cardiometabolic health and support considering CKM burden in clinical risk assessment across subgroups.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH160
Topic
Epidemiology & Public Health
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Geriatrics, SDC: Oncology